Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

NCT06343792 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Steroid Refractory GVHD

Interventions

DRUG: RLS-0071

Sponsor

ReAlta Life Sciences, Inc.

Collaborators

[object Object]